SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
Batra Centre
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278
E-mail : info@solara.com
www.solara.co.in

February 22, 2020

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: SOLARA

Dear Sir / Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

"Solara Puducherry and Mangalore facilities complete USFDA Inspection with zero 483s"

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

SOLARA ACTIVE PHARMA SCIENCES LIMITED

Encl:- as above

PRESS RELEASE
FOR IMMEDIATE CIRCULATION

SOLARA
Active Pharma Sciences

WWW.SOLARA.CO.IN | BSE:541540 NSE:SOLARA BLOOMBERG:SOLARA:IN | SECTOR:PHARMACEUTICALS

USFDA conclude inspections at Solara's Puducherry and Mangalore facility with zero 483 observations

Chennai, India – Feb 22,2020: Solara Active Pharma Science Limited (Solara), a leading Active Pharmaceutical Ingredient provider is pleased to announce that the US Food and Drug Administration (USFDA) has completed two successful inspections of Solara's state of the art manufacturing facilities at Puducherry and Mangalore. The inspection established that the two sites are in an **"Acceptable State of Compliance" with Zero Form 483** inspectional observations from USFDA. The agency with their designated auditors inspected the two facilities from 17th to 21st February 2020.

The Puducherry API manufacturing facility is our centre of excellence for the manufacturing of Ibuprofen and its derivative APIs. The facility was established in the year 1986 and is one of the largest Ibuprofen manufacturing sites in the world. This site is inspected by various Regulatory Authorities including USFDA, MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS.

Solara's multiproduct manufacturing site at Mangalore was established in 1997 and has best in class infrastructure and capabilities to produce niche high-value APIs and API intermediates. In addition to the USFDA, the site also maintains its regulatory status with other leading global agencies such as MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS.

Commenting on the audit outcomes, Jitesh Devendra,MD said *"We are very happy with the successful Zero 483 outcome of our two sites within the same week. This continues to demonstrate our relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy. We remain agile to the increasing requirements on quality and compliance, and I am confident that we will sustain our quality culture and anchor it further."*

These inspection outcomes are Solara's fourth consecutive US FDA audit with "Zero 483s". In Dec'18,Jan'19 and Jul'19, the USFDA concluded the inspections at our facilities at Solara Research Centre(SRC), Chennai and API manufacturing sites at Ambernath and Cuddalore with zero 483s.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal
Investor Relations Consultant
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory contact

Murali Krishna S
Raghavan. V
✉ investors@solara.co.in
✆ +91 44 4344 6700